| Firm | Analyst |
| Raymond James | Michael Freeman |
| Stifel GMP | Justin Keywood |
| Paradigm Capital | Scott McAuley, PhD |
| Maxim Group | Michael Okunewitch |
| Research Capital | Andre Uddin |
NervGen Pharma Corp. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding NervGen Pharma Corp.’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of NervGen Pharma Corp. or its management. NervGen Pharma Corp. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
NervGen Pharma Corp (“NervGen”) (TSXV: NGEN) (OTCQB: NGENF), is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic disorders. NervGen’s lead candidate, NVG-291, is a first- and potential best-in-class candidate being evaluated in the Phase 1b/2a CONNECT SCI Study in individuals living with spinal cord injury.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: [email protected]